Impel Pharmaceuticals Inc.
IMPL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $12,652 | $668 | $0 | $0 |
| % Growth | 1,794% | – | – | – |
| Cost of Goods Sold | $6,495 | $691 | $0 | $0 |
| Gross Profit | $6,157 | -$23 | $0 | $0 |
| % Margin | 48.7% | -3.4% | – | – |
| R&D Expenses | $11,456 | $20,563 | $27,285 | $28,812 |
| G&A Expenses | $77,885 | $50,900 | $18,049 | $12,754 |
| SG&A Expenses | $77,885 | $50,900 | $18,049 | $12,754 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$408 | $0 |
| Operating Expenses | $89,341 | $71,463 | $45,334 | $41,566 |
| Operating Income | -$83,184 | -$71,486 | -$45,334 | -$41,566 |
| % Margin | -657.5% | -10,701.5% | – | – |
| Other Income/Exp. Net | -$23,128 | -$5,048 | -$463 | -$263 |
| Pre-Tax Income | -$106,312 | -$76,534 | -$45,797 | -$41,829 |
| Tax Expense | $23,128 | $2 | $1 | $30 |
| Net Income | -$129,440 | -$76,536 | -$45,798 | -$41,859 |
| % Margin | -1,023.1% | -11,457.5% | – | – |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| % Growth | -5.3% | -50.1% | -9.4% | – |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23,445 | 14,600 | 13,139 | 13,139 |
| Weighted Avg Shares Out Dil | 23,445 | 14,600 | 13,139 | 13,139 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,584 | $2,250 | $0 | $417 |
| Interest Expense | $13,835 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,201 | $1,088 | $1,077 | $722 |
| EBITDA | -$91,276 | -$70,398 | -$44,257 | -$40,844 |
| % Margin | -721.4% | -10,538.6% | – | – |